跳至主要内容
临床试验/CTIS2022-502061-17-00
CTIS2022-502061-17-00进行中(未招募)1 期

uwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-label, Non-controlled study (NuDIMENSION) - GENA-23

Octapharma AG0 个研究点目标入组 22 人开始时间: 2023年1月31日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Octapharma AG
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 65+(—)

入选标准

  • Women/girls with haemophilia A (FVIII activity [FVIII:C] =1 - <40%) according to medical history, At least 12 years of age, Scheduled to undergo major elective surgery requiring FVIII treatment, Freely given written informed consent

排除标准

  • Coagulation disorder other than haemophilia A, Present or past FVIII inhibitors (=0.6 Bethesda units [BU]/mL), Severe liver or kidney disease (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels >5 times the upper limit of normal; or creatinine >120 µmol/L), Pregnancy, Current participation in another interventional clinical trial, Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit, Known hypersensitivity to Nuwiq’s active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188), Already had surgery in this study

研究者

发起方
Octapharma AG

相似试验